PTCT
PTC Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website cbio.com
- Employees(FY) 1402
- ISIN US69366J2006
Performance
-3.99%
1W
+12.9%
1M
+59.1%
3M
+36.88%
6M
+81.39%
YTD
+93.53%
1Y
Profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Technical Analysis of PTCT 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-04 07:15
- 2024-12-03 13:37
- 2024-12-03 13:36
- 2024-12-03 07:55
- 2024-12-03 06:25
- 2024-12-03 04:42
Novartis and PTC Therapeutics link to develop Huntington’s therapy(Pharmaceutical Technology)
- 2024-12-02 16:02
- 2024-12-02 13:27
Sector Update: Health Care(MT Newswires)
- 2024-12-02 12:58
- 2024-12-02 12:40
- 2024-12-02 11:29
- 2024-12-02 09:32
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone(Investor's Business Daily)
- 2024-12-02 07:31
- 2024-12-02 07:00
- 2024-12-01 23:40
- 2024-12-01 18:00
- 2024-12-01 16:56
Novartis wagers billions of dollars on PTC Huntingtons drug(Yahoo Finance)
- 2024-11-28 07:11
- 2024-11-27 10:12
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down(Clinical Trials Arena)
- 2024-11-27 07:51
- 2024-11-27 07:26
- 2024-11-27 07:00
- 2024-11-27 05:38
Kronos, Idorsia plan layoffs; PTC shelves ALS drug(BioPharma Dive)
- 2024-11-26 18:00
- 2024-11-26 17:23
- 2024-11-26 16:30
- 2024-11-26 03:30
- 2024-11-25 16:30
- 2024-11-25 03:30
- 2024-11-14 13:46
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.